---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-24-000015"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T11:12:05.051461+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Supernus Q4 rev $164.3M, Qelbree +97% YoY; FY23 GAAP op loss $5.3M, non-GAAP op earnings $125.1M

## Summary
- Q4 2023 total revenues $164.3M (GAAP); full year 2023 total revenues $607.5M, down 9% YoY.
- Qelbree net sales Q4 $46.4M (+97% YoY), full year $140.2M (+129%); GOCOVRI Q4 $32.0M (+10%), full year $119.6M (+15%).
- Full year 2023 GAAP operating loss $(5.3)M; non-GAAP operating earnings $125.1M. GAAP net earnings $1.3M ($0.02 diluted EPS).
- FY2024 guidance: total revenues $580-$620M; non-GAAP operating earnings $80-$110M; expects generic erosion of Trokendi XR/Oxtellar XR from Sep 2024.
- Pipeline: SPN-830 PDUFA April 5, 2024; Phase IIb SPN-820 data H1 2025; interim Phase IIa SPN-817 data May 2024.

## SEC filing metadata
- accession: 0001356576-24-000015
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000015/0001356576-24-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000015/supn-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-24-000015
- JSON: https://secwatch.observer/filing/0001356576-24-000015.json
- Plain text: https://secwatch.observer/filing/0001356576-24-000015.txt

## Key facts
- Earnings Releases
  SUPERNUS PHARMACEUTICALS, INC. reported Full year 2023 results: revenue Total revenues (GAAP) of $607.5 million.
  - Period: Full year 2023
  - Revenue: Total revenues (GAAP) of $607.5 million
  - Result: reported results
  source text: For the full year ended December 31, 2023, total revenues and total net product sales were $607.5 million and $573.9 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000015/0001356576-24-000015-index.htm
- Earnings Releases
  SUPERNUS PHARMACEUTICALS, INC. reported Fourth quarter 2023 results: revenue Total revenues (GAAP) of $164.3 million.
  - Period: Fourth quarter 2023
  - Revenue: Total revenues (GAAP) of $164.3 million
  - Result: reported results
  source text: For the three months ended December 31, 2023, total revenues and total net product sales (GAAP) were $164.3 million and $156.0 million, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356576/000135657624000015/0001356576-24-000015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.